| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/10/2001 | US6214869 Heterocyclic cis cyclopropane derivatives as melatonergic agents |
| 04/10/2001 | US6214867 Anticonvulsant derivatives useful in treating essential tremor |
| 04/10/2001 | US6214862 Analyzing proteasome sensitivity proteolysis |
| 04/10/2001 | US6214858 Caspases and apoptosis |
| 04/10/2001 | US6214856 Treating neurodegenerative disorders, e.g., alzheimer's disease, strokes, traumatic brain injury; antiischemic agents; muscular dystrophy; also cataracts; platelet aggregation |
| 04/10/2001 | US6214847 Treatment of cognitive or neurological dysfunction |
| 04/10/2001 | US6214846 Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents |
| 04/10/2001 | US6214844 Substituted imidazole compounds |
| 04/10/2001 | US6214839 Substituted 6-alkylphenanthridines |
| 04/10/2001 | US6214837 Treating said condition with combination of antihistamines (loratodine) and quinine hydrochloride |
| 04/10/2001 | US6214829 Piperazine compounds, their preparation, and methods of using them |
| 04/10/2001 | US6214822 Substituted aza and diazacycloheptane and cyclooctane compounds and their use |
| 04/10/2001 | US6214817 Nitrogen macrocycle complexes with manganese and iron |
| 04/10/2001 | US6214796 Administering a polypeptide growth factor for improved sensor motor deficit caused by injury |
| 04/10/2001 | US6214614 Cell cycle regulated repressor and DNA element |
| 04/10/2001 | US6214600 Polypeptide of defined amino acid sequence; treatment of alzheimer's disease, stroke, musculoskeletal disease, heart disease, kidney disease; anticarcinogenic/antiinflammatory agents; antiarthritic agents; diagnosis |
| 04/10/2001 | US6214379 Useful for adaptation to schedules, cycles and needs of individuals improving compliance with their therapy, reducing amounts required daily to less than conventionally utilized, and minimizing undesired effects; drug delivery |
| 04/10/2001 | US6214354 Immunizing a person older than fifty who has had varicella or who has had a live varicella vaccine with immunologically effective amount of attenuated varicella zoster virus oka strain, where amount is at least 1,000 plaque forming units |
| 04/10/2001 | US6214348 Administering to the mammal a polypeptide comprising seq id no:2 in an amount sufficient to induce an immunological response to produce antibodies to seq id no:2 |
| 04/10/2001 | CA2200604C Novel production intermediate and process for producing pyridine derivative |
| 04/10/2001 | CA2165618C Tricyclic oxime ethers; process for preparing the same and pharmaceutical compositions containing them |
| 04/10/2001 | CA2133413C Indole derivatives as 5-ht1 antagonists |
| 04/10/2001 | CA2119661C New n-benzylpiperazine compounds, their preparation process and pharmaceutical compositions containing them |
| 04/10/2001 | CA2086974C R(+)-terazosin |
| 04/05/2001 | WO2001023598A1 41 human secreted proteins |
| 04/05/2001 | WO2001023590A2 22196, a novel human aminopeptidase |
| 04/05/2001 | WO2001023588A1 Human carboxypeptidases and polynucleotides encoding the same |
| 04/05/2001 | WO2001023584A1 Human ubiquitin protease |
| 04/05/2001 | WO2001023572A2 Polynucleotides and polypeptides encoded thereby |
| 04/05/2001 | WO2001023571A1 Methods and compositions relating to sodium channel beta1a subunits |
| 04/05/2001 | WO2001023570A2 Methods and compositions relating to sodium channel beta-1a subunits |
| 04/05/2001 | WO2001023554A1 The prv-1 gene and use thereof |
| 04/05/2001 | WO2001023551A1 Novel nicotinic acetylcholine receptor subunit, its isolation and use |
| 04/05/2001 | WO2001023547A1 26 human secreted proteins |
| 04/05/2001 | WO2001023546A1 37 human secreted proteins |
| 04/05/2001 | WO2001023425A1 Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
| 04/05/2001 | WO2001023408A1 5-hydroxysapogenin derivatives with anti-dementia activity |
| 04/05/2001 | WO2001023407A1 Sapogenin derivatives and their use in the treatment of cognitive dysfunction |
| 04/05/2001 | WO2001023406A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 04/05/2001 | WO2001023402A1 43 human secreted proteins |
| 04/05/2001 | WO2001023399A1 Compounds for the treatment of ischemia |
| 04/05/2001 | WO2001023391A1 Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents |
| 04/05/2001 | WO2001023390A2 Azepinoindole derivatives, the production and use thereof |
| 04/05/2001 | WO2001023389A2 Certain alkylene diamine-substituted heterocycles |
| 04/05/2001 | WO2001023388A2 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| 04/05/2001 | WO2001023387A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| 04/05/2001 | WO2001023386A2 Benzodiazepin derivatives, the production and use thereof |
| 04/05/2001 | WO2001023385A2 Novel tropane analogs |
| 04/05/2001 | WO2001023382A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/05/2001 | WO2001023381A1 Piperidine derivatives as reuptake inhibitors |
| 04/05/2001 | WO2001023380A1 Piperidine derivatives as serotonine reuptake inhibitors |
| 04/05/2001 | WO2001023379A1 Pharmaceutically active sulfonyl amino acid derivatives |
| 04/05/2001 | WO2001023378A1 Pharmaceutically active sulfonamide derivatives |
| 04/05/2001 | WO2001023377A2 Polymorphic salt |
| 04/05/2001 | WO2001023374A1 Piperazine derivatives as 5-ht1b antagonists |
| 04/05/2001 | WO2001023360A1 Aryl sulfonamide-substituted benzimidazol derivatives thereof as tryptase inhibitors |
| 04/05/2001 | WO2001023347A1 Novel aromatic compounds |
| 04/05/2001 | WO2001023064A1 Method and installation for setting in adsorbed state on a porous support active compounds contained in a product |
| 04/05/2001 | WO2001022997A1 Analgesics |
| 04/05/2001 | WO2001022987A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | WO2001022972A2 Immunostimulatory nucleic acids |
| 04/05/2001 | WO2001022967A1 Compositions having improved stability |
| 04/05/2001 | WO2001022966A1 Caspases and apoptosis |
| 04/05/2001 | WO2001022956A2 NOVEL COMBINATION OF LOTEPREDNOL AND β2-ADRENOCEPTOR AGONISTS |
| 04/05/2001 | WO2001022953A2 Use of retigabin for treating neuropathic pain |
| 04/05/2001 | WO2001022951A2 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| 04/05/2001 | WO2001022944A1 Oral controlled release formulations |
| 04/05/2001 | WO2001022940A1 Sustained release matrix systems for highly soluble drugs |
| 04/05/2001 | WO2001022937A1 Compositions of tocol-soluble therapeutics |
| 04/05/2001 | WO2001012602A8 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 04/05/2001 | WO2000073450A3 Cytoskeleton-associated proteins |
| 04/05/2001 | WO2000073334A3 Human sorting nexins |
| 04/05/2001 | WO2000069440A3 Nicotine delivery systems |
| 04/05/2001 | WO2000068198A3 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 04/05/2001 | WO2000066713A3 Materials and methods relating to neuronal development |
| 04/05/2001 | WO2000065027A3 Human gil-19/ae289 proteins and polynucleotides encoding same |
| 04/05/2001 | WO2000064474A8 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
| 04/05/2001 | WO2000060051A8 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 04/05/2001 | WO2000057877A8 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| 04/05/2001 | WO2000056891A3 Human transmembrane proteins |
| 04/05/2001 | WO2000056292A3 Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine |
| 04/05/2001 | WO2000055343A3 Retrovirus producting cells utilizing a high multiplicity of transduction |
| 04/05/2001 | WO2000053738A8 Methods and compositions for regulating memory consolidation |
| 04/05/2001 | WO2000052205A3 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 04/05/2001 | WO2000050398A3 Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
| 04/05/2001 | WO2000040228A3 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 04/05/2001 | WO2000032805A9 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
| 04/05/2001 | WO2000020450A9 Calcium channel alpha-2/delta gene |
| 04/05/2001 | WO1996018391B1 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor |
| 04/05/2001 | US20010000143 Using dimethyl ether and elevated temperature/pressure to dissolve the solid; releasing the pressure to precipitate the fine powder and expand the ether into a gas; drugs; vitamins; carotenoid, especially beta-carotene; foods; cosmetics |
| 04/05/2001 | DE19947235A1 Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten New combination of loteprednol and beta¶2¶-adrenoceptor agonists |
| 04/05/2001 | DE19947010A1 Das Gen PRV-1 und dessen Verwendung The PRV-1 gene and its use |
| 04/05/2001 | CA2659048A1 Use of retigabine for the treatment of neuropathic pain |
| 04/05/2001 | CA2640998A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 04/05/2001 | CA2388055A1 Immunostimulatory nucleic acids |
| 04/05/2001 | CA2387702A1 The prv-1 gene and use thereof |
| 04/05/2001 | CA2386346A1 Novel polynucleotides and polypeptides encoded thereby |
| 04/05/2001 | CA2386092A1 Piperidine derivatives |
| 04/05/2001 | CA2386085A1 Piperidine derivatives |
| 04/05/2001 | CA2386079A1 Compounds for the treatment of ischemia |